

CSU

WHEN H1-ANTIHISTAMINES ARE NOT ENOUGH  
**RETHINK TREATMENT. REIMAGINE POSSIBILITIES.**



**DUPIXENT**<sup>®</sup>  
 (dupilumab)

**A BIOLOGIC YOU KNOW — NOW APPROVED IN CHRONIC SPONTANEOUS URTICARIA<sup>1</sup>**



# DUPIXENT CSU INDICATION LAUNCH



Friday November 8, 2024 7:00PM - 8:30PM

InterContinental Festival City, Dubai – AIRas Ballroom

**CHAIRPERSON**



**DR. MUNA AL MURRAWI**

President of the Emirates Dermatology Society, Consultant dermatologist and Chief of Dermatology services in Dr. Muna AlMurrawi Medical Center, Abu Dhabi, UAE

**SPEAKERS**



**DR. FATIMA ALBREIKI**

Scientific Committee Chairperson of Emirates Dermatology Society Consultant Dermatologist Chief of dermatology division at Tawam hospital Abu Dhabi, UAE



**DR. AHMED AMEEN**

Consultant Dermatology & Venerology, NMC Speciality Hospital Abu Dhabi, UAE



**PROF. MICHIIRO HIDE**

Professor in Dermatology and Director of Hiroshima City Hiroshima Citizens Hospital Japan



**DR. SHUAYB ELKHALIFA**

Consultant in Immunology and Allergy and Associate Professor at Cleveland Clinic, Abu Dhabi, UAE

# AGENDA

Friday November 8, 2024

Time	Title	Speaker	Chairperson
7:00-7:05	Sanofi Opening		
7:05-7:15	Understanding the Burden of CSU: Snapshot into Gulf	Dr. Fatima Albreiki	
7:15-7:35	An Expert's Dive into CSU: An Open Dialogue on Diagnosis, Management and Unmet Needs	Prof. Michihiro Hide Dr. Shuayb El Khalifa Dr. Ahmed Ameen Dr. Fatima Albreiki	
7:35-7:50	Journey Beneath the Skin: the Role of the Immune System, Itch and Neurons in CSU	Prof. Hide Michihiro	Dr. Muna Al Murrawi
7:50-8:05	Dupixent - NOW APPROVED for CSU patients CUPID program	Prof. Hide Michihiro	
8:05-8:15	From theory to practice	Dr. Fatima Albreiki Dr. Ahmed Ameen	
8:15-8:30	Panel Discussion and Q&A	All	



For further medical information, please contact: For UAE ☎ 800 MEDICAL Toll-Free Number. For all Gulf countries ☎ +971 45 50 38 63 or email: medical-information.gulf@sanofi.com  
 To report an adverse event, please call: +971 561747001 or e-mail: gulf.pharmacovigilance@sanofi.com  
 MAT-AE-2400680/V1/October 2024



**sanofi**